How should health-related quality of life be assessed in patients with COPD?

Chest

Volumn 117, Issue 2 SUPPL., 2000, Pages 54S-57S

  Mahler, Donald A ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Bronchodilator therapy; Disease specific instrument; Dyspnea; Generic health measure; Minimum clinically significant change

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISABILITY; DYSPNEA; EXERCISE TOLERANCE; HEALTH STATUS; HUMAN; LUNG FUNCTION TEST; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; TREATMENT OUTCOME;

EID: 0034002446     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.2_suppl.54S     Document Type: Article

References (25)

1. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334:835-840
2. Guyatt GH, Feeny DH, Patrick DL. Measuring heath-related quality of life. Ann Intern Med 1993; 118:622-629
3. Feinstein AR. An additional basic science for clinical medicine: IV. The development of clinimetrics. Ann Intern Med 1983; 99:843-848
4. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42:773-778
5. Mahler DA, Jones PW. Measurement of dyspnea and quality of life in advanced lung disease. Clin Chest Med 1997; 18:457-469
6. Bergner M, Bobbitt RA, Pollard WE, et al. The Sickness Impact Profile: validation of a health status measure. Med Care 1976; 14:57-67
7. Ware JE Jr, Sherbourne CD. The MOS short-form health survey (SF-36): 1. Conceptual framework and item selection. Med Care 1992; 30:473-483
8. Hunt SM, McEwen J, McKenna SP. Measuring health status. London, UK: Groom Helm, 1986
9. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327
10. Tu SP, McDonell MB, Spertus JA, et al. A new self-administered questionnaire to monitor health-related quality of life in patients with COPD. Chest 1997; 112:614-622
11. Harper R, Brazier JE, Waterhouse JC, et al. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax 1997; 52:879-887
12. Mahler DA, Faryniarz K, Tomlinson D, et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest 1992; 102:395-401
13. Stewart AL, Hays RD, Ware Jr JE. The MOS short-form general health survey. Med Care 1988; 26:724-735
14. Hajiro T, Nishimura K, Tsukino M, et al. Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:785-790
15. Mahler DA, Mackowiak JI. Evaluation of the Short-Form 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest 1995; 107:1585-1589
16. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127:1072-1079
17. Van Schayck CP, Rutten-van Mölken MPMH, van Doorslaer EKA, et al. Two-year bronchodilator treatment in patients with mild airflow obstruction. Chest 1992; 102:1384-1391
18. Jones PW. Dyspnea and quality of life in chronic obstructive pulmonary disease. In: Mahler DA, ed. Dyspnea. New York, NY: Marcel Dekker, 1998:199-220
19. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in chronic airflow limitation. Am Rev Respir Dis 1987; 135:1069-1074
20. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283-1289
21. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-965
22. Mahler DA, Matthay RA, Snyder PE, et al. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis 1985; 131:22-25
23. Murciano D, Auclair MH, Pariente R, et al. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320:1521-1525
24. McKay S, Howie CA, Thomson AH, et al. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48:227-232
25. Mahon JL, Laupacis A, Hodder RV, et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest 1999; 115:38-48